| Identification | Back Directory | [Name]
N-CARBAMYL-L-GLUTAMIC ACID | [CAS]
1188-38-1 | [Synonyms]
OE 312
Carbaglu
N-Cbm-Glu-OH
carglumicaci
CargluMic Acid
ureidoglutaricacid
n-carbamylglutamate
carbamylglutamicacid
N-Carbamyl-L-glutamic
N-Carbamyl-L-glutamate
carbamino-l-glutamicacid
N-CarbaMoyl L- GlutaMate
(2S)-2-ureidoglutaric acid
N-CARBAMYL-L-GLUTAMIC ACID
N-CarbaMoyl-L-glutaMic Acid
N-CarbaMoyl-S-glutaMic Acid
(S)-2-Ureidopentanedioic acid
NCG,N-carbamyl-L-glutamic acid
Acide N-carbamoyl-L-glutamique
n-(aminocarbonyl)-l-glutamicaci
N-(AMinocarbonyl)-L-glutaMic Acid
L-Glutamic acid, N-(aminocarbonyl)-
N-CARBAMYL-L-GLUTAMIC ACID USP/EP/BP
N-carbamyl-L-glutamic acid crystalline
(2S)-2-(carbamoylamino)pentanedioic acid
(2S)-2-(aminocarbonylamino)pentanedioic acid
N-(Aminocarbonyl)-L-Glutamic Acid(Carglumic Acid) | [EINECS(EC#)]
601-569-3 | [Molecular Formula]
C6H10N2O5 | [MDL Number]
MFCD00047874 | [MOL File]
1188-38-1.mol | [Molecular Weight]
190.15 |
| Chemical Properties | Back Directory | [Melting point ]
174° | [Boiling point ]
438.1±45.0 °C(Predicted) | [density ]
1.499±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C
| [solubility ]
DMSO (Slightly), Methanol (Slightly, Sonicated) | [form ]
Solid | [pka]
3.71±0.10(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Uses]
carbamylphosphate synthetase activator | [Uses]
N-Carbamyl-L-glutamic Acid has been shown to have protective effects against ammonia intoxication and is used in the treatment of acute hyperammonemia. | [Definition]
ChEBI: A urea that is the N-carbamoyl derivative of L-glutamic acid. An orphan drug used to treat a deficiency in the enzyme N-acetylglutamate synthase, which leads to acute hyperammonaemia. | [Biological Activity]
N-Carbamyl-L-glutamic acid (carglumic acid) is use to study its potential as a replacement therapy for N-acetylglutamate synthetase (NAGS) deficiency and to tre at hyperammonemia. | [in vivo]
The results show that Carglumic acid, but not the vehicle control, markedly inhibits tumor growth. In the orthotopic pancreatic cancer model, tumor growth inhibition by Carglumic acid on day 21 is 80% (P<0.01). In the orthotopic triple-negative breast cancer model, tumor growth inhibition by Carglumic acid on day 20 is 82% (P<0.01). These results indicate that Carglumic acid suppresses tumor growth in pancreatic cancer and triple-negative breast cancer. On day 20, mean tumor growth inhibition in orally and intravenously treated mice is 55% and 93%, respectively, relative to untreated mice (P<0.01)[1]. |
|
|